Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biguanides and NIDDM.

C J Bailey1

  • 1Department of Pharmaceutical Sciences, Aston University, Birmingham, United Kingdom.

Diabetes Care
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Metformin, an oral glucose-lowering agent, effectively treats type 2 diabetes by increasing glucose utilization without stimulating insulin secretion. It offers benefits like weight management and improved lipid profiles, making it a valuable antihyperglycemic drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.

Clinical pharmacology and therapeutics·2015
Same author

Safety of antidiabetes medications: An update.

Clinical pharmacology and therapeutics·2015
Same author

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Diabetes, obesity & metabolism·2014
Same author

A cotyledon slice system for the electron autoradiographic study of the synthesis and intracellular transport of the seed storage protein of Vicia faba.

Planta·2014
Same author

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Diabetes, obesity & metabolism·2012
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Biguanides, including metformin and phenformin, were developed in 1957 for managing non-insulin-dependent diabetes mellitus (NIDDM).
  • Phenformin's use was limited due to lactic acidosis risk, whereas metformin, when prescribed correctly, presents a lower risk.
  • Metformin is now a cornerstone therapy, used alone or with sulfonylureas, for type 2 diabetes management.

Purpose of the Study:

  • To review the pharmacological properties and clinical applications of metformin in treating non-insulin-dependent diabetes mellitus (NIDDM).
  • To highlight metformin's mechanism of action, safety profile, and therapeutic advantages over other antidiabetic agents.

Main Methods:

  • Review of existing literature on biguanides, focusing on metformin's pharmacokinetics and pharmacodynamics.

Related Experiment Videos

  • Analysis of metformin's effects on glucose metabolism, insulin sensitivity, and associated metabolic parameters.
  • Evaluation of clinical outcomes, including efficacy, safety, and side effect profiles.

    • Main Results:

    • Metformin enhances insulin action at the postreceptor level, increasing glucose uptake and oxidative metabolism in peripheral tissues like muscle.
    • It increases glucose utilization in the intestine via nonoxidative metabolism, with lactate produced being utilized by the liver for gluconeogenesis.
    • Metformin does not stimulate insulin secretion, thus avoiding hypoglycemia, and has beneficial effects on weight and triglycerides, with potential vasoprotective properties.

    Conclusions:

    • Metformin is a safe and effective antihyperglycemic agent for type 2 diabetes, particularly beneficial for overweight, insulin-resistant patients.
    • Its unique mechanism, favorable side effect profile, and additional metabolic benefits position it as a primary treatment option.
    • Metformin's ability to improve insulin sensitivity and combat hypertriglyceridemia underscores its comprehensive role in managing NIDDM.